Evidence map›Paper›PMID 28418232›Full record

ArticleJournal of the International AIDS Society2017

High pre-exposure prophylaxis uptake and early adherence among men who have sex with men and transgender women at risk for HIV Infection: the PrEP Brasil demonstration project.

Brenda Hoagland, Ronaldo I Moreira, Raquel B De Boni, Esper G Kallas, José Valdez Madruga, Ricardo Vasconcelos, Silvia Goulart, Thiago S Torres, Luana M S Marins, Peter L Anderson and 6 more

Erratum issuedOpen access · goldAbstract readMulticenter Study
In one paragraph

Article in Journal of the International AIDS Society, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 66 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed, 5 pooled it
8.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

66 citing papers in PubMed, 5 syntheses or guidelines pooled it, 155 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

6 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 2 countries.

Brenda HoaglandFIOCRUZ, Instituto Nacional de Infectologia Evandro Chagas, Rio de Janeiro, Brazil.
Ronaldo I MoreiraFIOCRUZ, Instituto Nacional de Infectologia Evandro Chagas, Rio de Janeiro, Brazil.
Raquel B De BoniFIOCRUZ, Instituto Nacional de Infectologia Evandro Chagas, Rio de Janeiro, Brazil.
Esper G KallasSchool of Medicine, Universidade de São Paulo, Brazil.
José Valdez MadrugaSchool of Medicine, Universidade de São Paulo, São Paulo, Brazil.
Ricardo VasconcelosSchool of Medicine, Universidade de São Paulo, Brazil.
Silvia GoulartSchool of Medicine, Universidade de São Paulo, São Paulo, Brazil.
Thiago S TorresFIOCRUZ, Instituto Nacional de Infectologia Evandro Chagas, Rio de Janeiro, Brazil.
Luana M S MarinsFIOCRUZ, Instituto Nacional de Infectologia Evandro Chagas, Rio de Janeiro, Brazil.
Peter L AndersonSkaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Denver, Aurora, CO, USA.
Paula M LuzFIOCRUZ, Instituto Nacional de Infectologia Evandro Chagas, Rio de Janeiro, Brazil.
Iuri da Costa LeiteFIOCRUZ, Instituto Nacional de Infectologia Evandro Chagas, Rio de Janeiro, Brazil.
Albert Y LiuSan Francisco Department of Public Health, Bridge HIV, San Francisco, CA, USA.
Valdilea G VelosoFIOCRUZ, Instituto Nacional de Infectologia Evandro Chagas, Rio de Janeiro, Brazil.
Beatriz GrinsztejnFIOCRUZ, Instituto Nacional de Infectologia Evandro Chagas, Rio de Janeiro, Brazil.
PrEP Brasil Study TeamClinical Trial Number 01989611
Instituto Evandro Chagas · BRUniversidade de São Paulo · BRSan Francisco Department of Public Health · USUniversity of Montana · US

Funding

The FIOCRUZ Therapeutic and Prevention HIV/AIDS Clinical Trials Unit (FioTrials)UM1AI069476 · NIAID · FUNDACAO OSWALDO CRUZ · PI BEATRIZ GRINSZTEJN · 2012 to 2026
$26.3M
NIAID NIH HHS UM1 AI069476
6 · The paper itself

Abstract

introductionThe efficacy of pre-exposure prophylaxis (PrEP) in preventing sexual acquisition of human immunodeficiency virus (HIV) is well established. Little is known about the feasibility of PrEP implementation in middle-income settings with concentrated epidemics among men who have sex with men (MSM) and transgender women (TGW).

methodsPrEP Brasil is a prospective, multicentre, open-label demonstration project assessing PrEP delivery in the context of the Brazilian Public Health System. HIV-uninfected MSM and TGW in 3 referral centres in Rio de Janeiro and São Paulo were evaluated for eligibility and offered 48 weeks of daily emtricitabine/tenofovir for PrEP. Concentrations of tenofovir diphosphate in dried blood spot samples (DBS) at week 4 after enrolment (early adherence) were measured. Predictors of drug levels were assessed using ordinal logistic regression models considering the DBS drug level as a 3 level variable (<350 fmol/punch, ≥350-699 fmol/punch and ≥700 fmol/punch).

results1,270 individuals were assessed for participation; n = 738 were potentially eligible and n = 450 were offered PrEP (PrEP uptake was 60.9%). Eligible but not enrolled individuals were younger, had lower HIV risk perception and had lower PrEP awareness. At week 4, 424 participants (of the 450 enrolled) had DBS TFV-DP concentrations, 94.1% in the protective range (≥350 fmol/punch, consistent with ≥2 pills per week), and 78% were in the highly protective range (≥700 fmol/punch, ≥4 pills per week). Participants with ≥12 years of schooling had 1.9 times the odds (95%CI 1.10-3.29) of a higher versus lower drug level than participants with <12 years of schooling. Condomless receptive anal intercourse in the prior 3 months was also associated with higher drug levels (adjusted OR = 1.78; 95% CI 1.08-2.94).

conclusionThe high uptake and early adherence indicate that PrEP for high-risk MSM and TGW can be successfully delivered in the context of the Brazilian Public Health System. Interventions to address disparities on PrEP awareness and HIV risk perception among the younger and less educated are urgently needed in order to maximize the impact of this prevention strategy on the reduction of HIV infection among MSM and TGW in Brazil.

Indexed as

Homosexuality, MaleMedication AdherencePre-Exposure ProphylaxisTransgender PersonsAdolescentAdultAnti-HIV AgentsBrazilEmtricitabineFemaleHIV InfectionsHumansLongitudinal StudiesMaleProspective StudiesSexual BehaviorAnti-HIV AgentsEmtricitabineTenofovirDRUG LevelsHIV preventionMSMPre-exposure prophylaxisPrEP adherencePrEP uptaketransgender women

Identifiers

PMID28418232
PMCPMC5515021
OpenAlexW2606947681

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.